PURPOSE: Late recurrence of renal cell carcinoma (RCC) is not a rare event.
The aim of this retrospective study was to investigate the clinico-pathological features and the outcome of patients (pts) treated with sorafenib, sunitinib and pazopanib for late-relapsing renal cell carcinoma (LR-RCC).
MATERIALS AND METHODS: Data were collected from 21 Italian centers involved in the treatment of metastatic RCC. Late relapse was defined as >5 yrs after initial radical nephrectomy.
RESULTS: 2490 pts were screened and 269 pts (11%) were included. First-line therapy was sunitinib in 190 pts (71%), sorafenib in 58 pts (21%) and pazopanib in 21 pts (8%). The median progression-free survival (PFS) was 20.0 months (95% CI 17.0-25.1) for sunitinib and 14.1 months for both sorafenib (95% CI 11.0-29.0) and pazopanib (95% CI 11.2-NR). On multivariate analysis, MSKCC score and metastases to lymph nodes, liver, and brain were associated with worst overall survival, while pancreatic metastases were associated with longer survival. Furthermore, age, MSKCC score and brain metastases were associated with worst Progression-free survival.
CONCLUSIONS: Pts with LR-RCC seem to present a characteristic pattern of metastatic spread, without showing significant differences in terms of PFS among sorafenib, sunitinib and pazopanib.
Written by:
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Are you the author?
Institution(S): See publishing journal.
Reference: J Urol. 2014 Jul 18. pii: S0022-5347(14)03958-5.
doi: 10.1016/j.juro.2014.07.011
PubMed Abstract
PMID: 25046616